Bayer HealthCare will be publishing new data from a pivotal phase III trial of its metastatic colorectal cancer treatment regorafenib this month.
The company will attend the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in order to showcase data from the international study, known as Correct.
A total of 760 patients were enrolled in the trial in order to evaluate the efficacy of regorafenib plus best supportive care among patients whose disease has progressed after standard therapies, compared to placebo.
Bayer already confirmed in October 2011 that the study had met its primary endpoint by offering significant improvement to overall survival rates, allowing the company to continue the study unblinded.
Data from this trial will be used to support regulatory submissions for the drug in 2012.
Regorafenib has been earmarked by its manufacturer as offering potential blockbuster commercial potential once approved, representing one of a number of promising oncology compounds in Bayer's pipeline.